Clinical Trials Logo

Clinical Trial Summary

Endoscopic retrograde cholangio-pancreatography (ERCP) is the most commonly used technique for diagnosis and treatment in the treatment of bile duct diseases including bile duct cholelithiasis and malignant/benign biliary obstruction. In particular, ERCP is an essential procedure for the removal of bile duct gallstones and bile drainage in malignant/benign biliary obstruction patients. Among ERCP-related complications, especially "post-ERCP pancreatitis (PEP)", which occurs due to the anatomical structure of the pancreatic biliary system, statistically occurs in about 5-10% of patients who first received ERCP. It is known, and treatment for PEP is the same as treatment for general acute pancreatitis but is known to have a relatively worse prognosis. The basis of treatment for acute pancreatitis is a conservative treatment based on fasting and fluid treatment, and starting oral diet after abdominal pain and pancreatic enzyme levels (amylase/lipase) normalized. However, a recent study reported that early oral diet could improve the patient's prognosis. According to a systematic review of 11 randomized trial papers by Valerie et al., it was reported that the early diet had the effect of reducing hospital stay without increasing adverse events when comparing the prognosis of the early refeeding group and delayed refeeding group. This result is theoretically considered to be because the oral diet has the advantage of increasing intestinal permeability, gut motility and reducing the likelihood of pancreatic necrosis/ infection compared to the parenteral diet. As above, PEP has the same treatment method as general acute pancreatitis but is known to have a relatively worse prognosis. However, the effect of an early diet recently attempted in acute pancreatitis has not been reported in patients with PEP. Therefore, we investigate the effects of early and delayed diets on the prognosis of patients with PEP through a prospective multicenter study.


Clinical Trial Description

1. Selection of research subjects A total of 80 patients, who have occurred pancreatitis after ERCP, will be enrolled at Yonsei University Sinchon Severance Hospital, Seoul National University Hospital, Dongguk University Ilsan Hospital, Gachon University Gil Hospital, Gyeongsang National University Changwon Hospital, Kyungpook National University Hospital, Seoul St. Mary's Hospital, Korea University Ansan Hospital, Pusan National University Hospital. The purpose and contents of this clinical trial are informed in detail to the subject and consent is obtained. 2. Evaluation of eligibility Eligibility is determined based on the basic patient data including physical examination, vital signs, body measurements, medical history, concomitant drugs, laboratory tests, and other basic examinations made at the first visit. 3. Grouping and randomization After ERCP was performed, the study subjects who were judged to have PEP according to enroll criteria were divided into early and delayed refeeding groups using a random number table and assigned 1:1 to proceed with the study. 4. Timing of refeeding In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. In the delayed refeeding group, oral diet is started after confirmation of restoring of normal bowel sound, pain decreasing below VAS 2. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability. 5. Interruption of refeeding In both early and delayed refeeding groups, the oral diet is stopped when the pain scale the patient complains after starting oral diet increases to VAS 5 points or more, or the patient refuses to eat due to abdominal pain or other reasons. The diet is restarted after the amylase/lipase level decreases below the upper normal limit, the patient's pain has disappeared, and the bowel movement is restored. 6. Dropout criteria 1. In the case of delayed diet group when symptoms persist for more than 96 hours and cannot start a diet 2. When fasting is necessary for other reason, such as an imaging test or endoscopy 3. When it is determined that a parenteral diet is necessary for reasons such as difficulty swallowing 4. When the researcher judged that the clinical trial cannot be continued 7. Discharge criteria and hospitalization period for PEP If the patient is tolerable for more than 24 hours after the soft diet (abdominal pain improvement, lab amylase/lipase level decreases to less than 2 times the upper normal limit, it is judged that PEP has improved and the discharge criteria have been satisfied. From the point of diagnosis of PEP to the point of time when the discharge criteria are satisfied is defined as the "hospitalization period for PEP". ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04750044
Study type Interventional
Source Yonsei University
Contact Jung Hyun Jo
Phone +82-2-2228-2274
Email junghyunjo83@yuhs.ac
Status Recruiting
Phase N/A
Start date February 18, 2021
Completion date December 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT02476279 - Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis Phase 3
Unknown status NCT01771419 - Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct N/A
Completed NCT04876768 - Effects of High FIO2 on Post-ERCP Pancreatitis. N/A
Not yet recruiting NCT06250803 - Early Pancreatic Stent Placement for Preventing PEP N/A
Completed NCT01912716 - Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis Phase 2/Phase 3
Terminated NCT00820612 - Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients Phase 4
Completed NCT03643900 - The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis N/A
Terminated NCT03749590 - Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis. Phase 3
Recruiting NCT03708458 - Pharmacological Prophylaxis of Post- Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis Phase 4